Hero image with Pittsburgh background pittplusme.org/study/1706

STUDY BASICS

Have you been diagnosed with metastatic castration-resistant prostate cancer? If so, you may be eligible for a research study to help find out what effects, good and bad, that an investigational drug called tazemetostat has on you and your prostate cancer. Reimbursement for study visits is provided.


IRB:
  SSU00115912 - Epizyme, Inc. - EZH-1101, A PHASE 1B/2 OPEN-LABEL STUDY EVALUATING TAZEMETOSTAT IN COMBINATION WITH ENZALUTAMIDE OR ABIRATERONE/PREDNISONE IN CHEMOTHERAPY NAIVE SUBJECTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (Pro00038038)

RESEARCH AREAS:
  Featured Research

Age Range
AGE:   18 and up

Duration DURATION:  28 months
VISITS:  Multiple visits

Location LOCATION: 
UPMC Hillman Cancer Center - Shadyside
Compensation COMPENSATION: 

$50 per visit

Phone Number PHONE NUMBER:
1-866-438-8230
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In
Search Icon pittplusme.org/study/1706
OR
Phone Number PHONE NUMBER:
1-866-438-8230

MEET THE RESEARCHER


Leonard Appleman

Leonard J. Appleman, MD, PhD, is an Associate Professor of Medicine in the Division of Hematology/Oncology. A graduate of New York University School of Medicine, Dr. Appleman’s research interests include the development of novel therapeutics for kidney cancer, prostate cancer, and other malignancies.




PittPlusMe.org 1-866-438-8230 PittPlusMe@pitt.edu
@PittPlusMe share tweet